Dr. Hongyang Wang, a professor, chief physician and doctoral supervisor, currently serves as the director of National Centre for Liver Cancer of China, and the director of International Cooperation Laboratory on Signal Transduction in Eastern Hepatobiliary Surgery Hospital, Shanghai, China. Dr. Wang was selected as a member of Chinese Academy of Engineering in 2005 and as a member of the World Academy of Sciences in 2011. In 2015, Wang set up the Chinese Society of Clinical Precision Medicine as chairman. In 2017, she was selected as vice president of the Chinese Anti-Cancer Association and Shanghai Medical Association.
Devoting to the research of liver diseases and tumors, Dr. Wang has authored more than 200 publications. Additionally, 14 patents of hers have been warranted, including 2 international authorizations. She researched and developed the Glypican-3 diagnostic kit to diagnose hepatocellular carcinoma, especially for alpha fetoprotein (AFP)-negative patients. The Kit was approved by China Food and Drug Administration (CFDA) in 2014. Dr. Wang has received a lot of honors, such as National Awards for Science and Technology Progress (Innovation Team Award), National Natural Science Award (Grade II), Shanghai Natural Science Award (Grade I), Shanghai Medical Science Technology Award (Grade I), Science and Technology Award of HO LEUNG HO LEE FOUNDATION, and Scientist and Engineer Award of Asia of the AMOREPACIFIC Award for Outstanding Women in Sciences. Dr. Wang has been successively awarded Merit Citation Class I, Merit Citation Class II, and Merit Citation Class III.
Dr. Wang’s research focuses on prevention, diagnosis and treatment of liver cancer in China. Her research team is interested in molecular mechanisms and translational medicine research of tumors. Additionally, Wang’s group has made major contributions to molecular mechanisms of carcinogenesis, transformation between inflammatory and carcinoma, and signaling network regulations of liver cancer.